Verici Dx plc (VRCI.L)
- Previous Close
1.6250 - Open
1.5000 - Bid 1.5000 x --
- Ask 1.7500 x --
- Day's Range
1.5000 - 1.7500 - 52 Week Range
1.0000 - 8.6930 - Volume
6,811 - Avg. Volume
1,404,840 - Market Cap (intraday)
3.941M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.
www.vericidx.com19
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VRCI.L
View MorePerformance Overview: VRCI.L
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRCI.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRCI.L
View MoreValuation Measures
Market Cap
3.94M
Enterprise Value
-998.43k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.98
Price/Book (mrq)
0.53
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-110.99%
Return on Assets (ttm)
-26.14%
Return on Equity (ttm)
-58.12%
Revenue (ttm)
4.33M
Net Income Avi to Common (ttm)
-4.81M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
7.01M
Total Debt/Equity (mrq)
4.65%
Levered Free Cash Flow (ttm)
-3.67M